Resveratrol is 'as close to a miraculous molecule as you can find' — a description Sinclair gave in a 2003 interview with the journal Science, framing the compound as an unusually powerful, broadly beneficial candidate anti-aging therapeutic ahead of any human clinical evidence.
A testimonial-tier claim (Sinclair’s own promotional framing, given to a journalist rather than published as a scientific finding), documented in KFF Health News’ 2019 retrospective. It set the promotional tone that carried resveratrol from a single yeast experiment to a $720 million pharmaceutical acquisition. It is marked refuted here on the same basis as the mechanistic SIRT1-activation claim: the compound’s flagship clinical trial (SRT501 in multiple myeloma) was terminated for a serious adverse event, and no resveratrol-based drug ever reached approval.
Appears in
Sources
- A 'Fountain Of Youth' Pill? Sure, If You're A Mouse. — Taylor, Marisa. A Fountain Of Youth Pill? Sure, If You're A Mouse. KFF Health News, 11 February 2019.
- A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and/or refractory multiple myeloma — Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, Jacobson E, Gumbleton T, Oakervee H, Cavenagh J. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2013;160(5):714-717. DOI: 10.1111/bjh.12154.